 |
*Read Disclaimer Sponsored Content |
|
July 10, 2026 | Unsubscribe |
Hello! |
New Alert: VolitionRx Limited (NYSE American: VNRX) |
VNRX is our new NYSE American high growth biotech alert. |
We were amongst the first to bring this company to your attention – after which it rallied +53% in just over a week. |
Since then, we have been monitoring VNRX closely as the chart has been building a very strong base. |
Now, we believe it could be positioned for another big breakout higher. |
VNRX trades for under 2.00 which means momentum can build very quickly. |
In addition, the company has announced multiple developments recently. |
VNRX is a NYSE American listed “multi-national epigenetics company” that is “developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis”. |
Epigenetic changes can be detected before the diseased cells themselves become abnormal enough to show up in traditional biopsies, and oftentimes before the first symptoms are felt. |
VNRX is “dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, disease and treatment monitoring”. |
The company’s “patented Nucleosomics™ technology” “detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of disease enabling early detection and potentially a better way to monitor disease progression and a patient’s response to treatment”. |
Based on this core, “cutting-edge technology” VNRX has “developed a portfolio of Nu.Q® assays which are simple, low-cost, accessible, routine blood tests”. |
Early detection and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. |
Here is a number that puts everything else in context: |
Sadly, cancer is "a leading cause of death worldwide, accounting for nearly 10 million deaths in 2022." |
The single most powerful determinant of whether a patient survives is how early it is caught. |
Stage I survival rates for most cancers exceed 90%. |
By Stage IV, many of those same cancers drop below 20%. |
The problem has always been detection. |
Tumors are often invisible to standard diagnostics until they have already spread. |
VNRX is working to change that with a simple blood test. |
And on March 18, 2026 they released data that stopped us in our tracks: |
“Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA” |
|
|
But that’s not all, on March 25, 2026 the company followed-up with another announcement: |
|
|
This could be a ground floor opportunity that wall street has not yet discovered. |
As the company further explains: |
“The biggest problem facing liquid biopsy worldwide is that the vast majority of circulating DNA in blood plasma samples comes from healthy cells, not cancer cells.” |
|
|
“In a world first new technology, Volition has overcome this hurdle and produced >99% pure cancer derived plasma DNA sequence sets for liquid biopsy.” |
|
|
Dr Jake Micallef, Chief Scientific Officer, Volition commented: |
"Removal of background normal cell free DNA from the blood to reveal this level of tumor derived DNA has been a long term goal of liquid biopsy. I believe this is a world-first and could, in my opinion, represent the biggest scientific breakthrough in cancer testing and monitoring in recent years. |
|
|
Furthermore: |
|
|
VNRX calls this “technology "Capture-Seq™" and it shows potential for both a multi-cancer early detection (MCED) approach, either alone or in combination with other tests, and the detection of Minimal Residual Disease”. |
Mr. Gael Forterre, Chief Commercial Officer, Volition added: |
"This scientific breakthrough has generated a lot of interest with potential licensing partners.” |
|
|
In the subsequent March 25, 2026 press release VNRX released “the data from a blinded validation cohort of 81 subjects (colorectal and lung cancer patients = 59, healthy controls = 22) and are extremely encouraged by the results, particularly in early-stage cancer detection”. |
“Details are summarized in the table below: |
|
|
The company believes “this technology could, with further development, become very widely used, in both the human and veterinary markets, and fits very well with our Nu.Q® product portfolio”. |
Capture-Seq is the emerging breakthrough - but it sits on top of a platform that is already generating real revenue and real clinical traction across multiple product lines: |
Nu.Q Vet Cancer Test is an “accessible and affordable screening test to aid in the early detection of cancer in dogs”. Nu.Q NETs assay is a “groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis”. Nu.Q® Discover is an “invaluable research tool for R&D professionals working within the field of Pharmacoepigenetics, studying the epigenetic basis for variation in response to drugs”. Nu.Q® Cancer “encapsulates a range of simple, cost effective blood-based assays”
|
The company has announced multiple accomplishments recently. |
Key highlights from May 27, 2026 press release: |
“First Quarter Revenue Growth: Reported $1M of revenue in the first quarter of 2026, representing a 300% increase year-over-year.” “Feline Lymphoma Manuscript Submission: Formally submitted the clinical manuscript for the Nu.Q® Vet cancer test in cats; $5 million milestone payment anticipated subsequent to publication.” “Global Licensing Momentum: Company confirms active discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies, including for technical evaluations.” “Capture-Seq™ Platform: Paper submitted for peer review; validation cohort detected over 95% of Stage I and II cancers2; underscores a $23 billion1 annualized opportunity in cancer detection.” “Sepsis & NETosis Validation: Inclusion of the Nu.Q® NETs assay in the $7.3 million government-backed DETECSEPS program in France.” “Breakthrough Finger-Prick Detection of Nucleosomes: Expanding global market potential for sepsis testing using lateral flow.” “European Lung Cancer Reimbursement: Formal reimbursement submission in France remains on schedule, with routine clinical use expected by end of 2026.”
|
Unfortunately, “1 in 5 deaths worldwide are associated with sepsis”, the “body’s overactive and toxic response to an infection”. |
It is the “number 1 cause of death in hospitals” and contributes to a healthcare cost of “$62bn pa in USA alone”. |
Mr. Cameron Reynolds, Chief Executive Officer, Volition said: |
"The ability to rapidly identify high-risk patients at the Point-of-Care by quantifying their nucleosome levels using a finger-prick sample and simple lateral flow device could enable quicker clinical decision making and consequently better patient outcomes. |
|
|
"This is a potential gamechanger, not only in diseases where time is critical such as sepsis, but also in significantly expanding potential use cases beyond traditional hospital infrastructure. It also creates a compelling pathway into underserved low-income countries, where laboratory infrastructure may be weak or non-existent." |
|
|
On May 14, 2026, the company announced: |
“VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update” |
Cameron Reynolds, President and Group Chief Executive Officer, said: |
"We have made strong progress across all of our product pillars during the first quarter and indeed subsequent to quarter end. |
|
|
"We announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q® Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q® Vet platform. |
|
|
"We are working with our long-term collaborators at the Hospices Civils de Lyon, one of Europe's leading cancer centers, on the reimbursement submission for Nu.Q® Lung Cancer. Reimbursement is the last step on the path to the first use of Nu.Q® in routine clinical practice, an exciting prospect which is core to Volition's mission, using our tests to help save lives. |
|
|
"We reported two new, potentially large, clinical use cases for our Nu.Q® NETs assay beyond sepsis. In conjunction with the Mayo Clinic[1], we demonstrated Nu.Q® NETs' potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care. We also demonstrated potential use for patient management of a chronic disease, Hidradenitis Suppurativa,[2] which affects about 1% of the world's population. Both use cases have the potential to be large markets. |
|
|
"We are currently in discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies where our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue. |
|
|
"We are delighted to have grown the commercial interest in the first quarter, particularly with regards to our Capture-Seq™ technology, with an increase in discussions, including for technical evaluations. |
|
|
"Discussions are at various stages of the negotiation process across all our different pillars; our laser focus is on executing licensing agreements and we will update you as they progress." |
|
|
On May 27, the company announced: |
“VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets” |
|
|
Here are some of the company’s comments from this press release: |
“We have developed a truly remarkable, versatile platform and have further strengthened our Intellectual Property portfolio as we continue our licensing discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies. Our goal is to enter into licensing agreements and other arrangements that will bring revenue in the form of up front milestone payments, royalties and/or other recurring revenue.” |
|
|
“We are delighted to have grown the commercial interest in the first quarter, particularly with regards to our Capture-Seq™ technology, with an increase in discussions, including for technical evaluations. Discussions are at various stages of the negotiation process across all our different pillars; our laser focus is on executing licensing agreements and we will update you as they progress.” |
|
|
“Our vision is for our technologies to be incorporated into tests that will be used first by millions, and ultimately, hundreds of millions of people and animals a year, with our platform licensed to a range of large diagnostic and liquid biopsy companies (and governments) worldwide. Combining our groundbreaking technology with their installed base of laboratories, analyzer machines and sales forces around the world will achieve the optimal outcome for us – large companies have the resources to realize the opportunities better than Volition.” |
|
|
In June, the company also announced: |
“VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring” |
Dr. Jake Micallef, Chief Scientific Officer, Volition commented: |
"This filing yet again shows the breadth of utility of our technology: it claims the potential use of Volition's existing Nu.Q® NETs test for Ebola. The Nu.Q® NETs test quantifies circulating nucleosomes and Neutrophil Extracellular Traps (NETs) as early indicators of hyper-inflammation leading to septic shock and early mortality. |
|
|
"Our existing patented product portfolio includes the CE-Marked automated Nu.Q® NETs assay for use in centralized laboratories, in addition to the recently announced capillary blood finger-prick lateral flow detection (LFT). The LFT could offer an unprecedented bedside triage solution for severe filovirus outbreaks, creating a compelling pathway into underserved, resource constrained countries, where laboratory infrastructure may be weak or non-existent. |
|
|
"While existing Ebola diagnostics focus entirely on identifying the presence of the virus, Volition's technology focuses on the host's dysregulated immune response. The Nu.Q® NETs test measures H3.1 nucleosomes, which serve as an independent predictor of organ failure and mortality in patients with sepsis and COVID-19. Similarly, identification of elevated NETs levels prior to clinical deterioration may help field medics prevent disease spread and provide earlier, more effective treatment for Ebola-infected patients." |
|
|
Most recently, the company announced: |
“VolitionRx Announces Collaboration with Sysmex” |
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. |
Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today it supports the health of people in over 190 countries and regions worldwide. |
Gael Forterre, Chief Commercial Officer, Volition commented: |
"We are proud to have entered into this agreement with Sysmex, as we implement our strategy to out license our proprietary Nu.Q® NETs test to large companies with a worldwide presence, to leverage their knowledge of specific diseases, product development, regulatory experience and their installed base of proprietary analyzers. Sysmex is a global leader in the field of in vitro diagnostics for hemostasis and thrombosis, among other diseases, where Neutrophil Extracellular Traps ("NETS") play such an important role. |
|
|
"Following the successful transfer of our Nu.Q® NETs assay onto Sysmex's platform we are delighted to commence the optimization phase in diseases associated with NETosis. NETosis is implicated in a wide range of diseases, including sepsis and other acute and chronic diseases. |
|
|
"We believe that Volition's Nu.Q® NETs test could provide not only improved diagnostic information to aid clinical decision-making and personalized care, but could also be a low-cost test to continue to monitor a patient's condition. |
|
|
"The commercial opportunity for the Nu.Q® NETs assay is significant, with a Total Addressable Market of $3.8 billion[1]. |
|
|
"It is exciting to progress the collaboration with Sysmex and we look forward to a fruitful long-term partnership together." |
|
|
But that’s not all… |
This week, the company also announced: |
“VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test” |
Dr Andrew Retter, Medical Consultant, Volition said: |
"Nu.Q® Cancer represents a significant advancement in lung cancer patient management, offering clinicians an additional tool to enhance precision in treatment selection and monitoring and is a test we envisage will be used routinely in the clinic once approved. |
|
|
"We have worked closely with the Lyon team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q® in the management of cancer patients. These results indicate that measuring methylated nucleosome biomarker levels with the Nu.Q® test, at Non Small Cell Lung Cancer diagnosis, can provide valuable information about survival, progression-free survival and, crucially, enhance the identification of patients who may benefit from curative care1-4. |
|
|
"The integration of epigenetic biomarkers, such as circulating H3K27Me3-nucleosome, into personalized medicine frameworks holds great promise for refining patient stratification and treatment selection. |
|
|
The test is simple to complete and easy to implement, the new information helps to empower bedside clinicians and their patients to make better informed decisions on treatments and planning future care together." |
|
|
We believe VNRX could be positioned for big upside potential. |
Make sure to do your own due diligence. |
Sources: S, WHO, Cancer, Presentation, PR1, PR2, PR3, PR4, PR5, PR6, PR7, PR8, PR9, PR10, PR11, PR12, PR13, PR14, PR15, PR16, PR17, Website, Chart |
|
Happy Trading! |
|
AwesomeStocks Team |
|
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose. |
|
|
DISCLAIMER: |
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of AwesomeStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help. |
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete. |
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete. |
Owners and operators of the Publisher expect to be compensated eight thousand dollars by bank wire transfer on 7/10/26 for the distribution of this advertisement about VNRX dated 7/10/26. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 7/9/26 for the distribution of a prior advertisement about VNRX. Previously, owners and operators of the Publisher have been compensated eight thousand dollars by bank wire transfer on 5/12/26 for the distribution of a prior advertisement about VNRX. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time. |
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at info@AwesomeStocks.com to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: |
www.AwesomeStocks.com/Disclaimer and www.AwesomeStocks.com/Privacy-Policy |
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink. |
